Top

Published in:

01-02-2011 | Original Article

Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue

Authors: Yukie Araki, Masahiro Mizoguchi, Koji Yoshimoto, Tadahisa Shono, Toshiyuki Amano, Akira Nakamizo, Satoshi O. Suzuki, Toru Iwaki, Tomio Sasaki

Published in: Brain Tumor Pathology | Issue 1/2011

Abstract

Recent reports have suggested an important clinical role for hypermethylation of the O⁶-methylguanine-DNA-methyltransferase (MGMT) promoter in patients with glioblastomas. Whether MGMT protein expression is correlated with promoter hypermethylation and patient outcomes, however, has not been elucidated. Here we describe a quantitative digital method for assessment of MGMT-specific immunostaining, and analyze the relationship between expression levels and methylation status of the MGMT promoter. We investigated 46 tumors from patients who received a diagnosis of glioblastoma or gliosarcoma. Immunohistochemistry with anti-MGMT antibody and methylation-specific PCR using bisulfite-modified tumor DNA were performed. The digital assessment method used image-analysis software to determine a digital MGMT staining index, and the results were compared with those obtained via conventional visual assessments. The digital staining index clearly correlated with the methylation status of MGMT promoter. In addition, the index correlated with our observational results when nuclear and cytoplasmic staining were assessed in three different fields. Our digital assessment method enabled us to assess uncertain immunopositive samples objectively and quantitatively, which is an important consideration when examining heterogeneous cellular staining. We expect that this method will be useful for assessment of heterogeneous staining with any antibodies.

Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354CrossRefPubMed

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed

Liu L, Gerson SL (2006) Targeted modulation of MGMT: clinical implications. Clin Cancer Res 12:328–331CrossRefPubMed

Brell M, Tortosa A, Verger E et al (2005) Prognostic significance of O⁶-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 11:5167–5174CrossRefPubMed

Cankovic M, Mikkelsen T, Rosenblum ML et al (2007) A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest 87:392–397PubMed

Cao VT, Jung TY, Jung S et al (2009) The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery 65:866–875CrossRefPubMed

Karayan-Tapon L, Quillien V, Guilhot J et al (2010) Prognostic value of O(6)-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol 97:311–322CrossRefPubMed

Parkinson JF, Wheeler HR, Clarkson A et al (2008) Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol 87:71–78CrossRefPubMed

Sonoda Y, Yokosawa M, Saito R et al (2010) O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol 15:352–358CrossRefPubMed

10.

Maxwell JA, Johnson SP, Quinn JA et al (2006) Quantitative analysis of O⁶-alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther 5:2531–2539CrossRefPubMed

11.

Metellus P, Coulibaly B, Nanni I et al (2009) Prognostic impact of O⁶-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer 115:4783–4794CrossRefPubMed

12.

Sasai K, Nodashira M, Nishihara H et al (2008) Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O⁶-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis. Am J Surg Pathol 32:1220–1227CrossRefPubMed

13.

Preusser M, Janzer RC, Felsberg J et al (2008) Anti-O⁶-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18:520–532PubMed

14.

Anda T, Shabani HK, Tsunoda K et al (2003) Relationship between expression of O⁶-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis. Neurol Res 25:241–248CrossRefPubMed

15.

Preusser M (2009) MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. Histol Histopathol 24:511–518PubMed

16.

Felsberg J, Rapp M, Loeser S et al (2009) Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 15:6683–6693CrossRefPubMed

17.

Grasbon-Frodl EM, Kreth FW, Ruiter M et al (2007) Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 121:2458–2464CrossRefPubMed

18.

Mollemann M, Wolter M, Felsberg J et al (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379–385CrossRefPubMed

19.

Nakagawa T, Ido K, Sakuma T et al (2009) Prognostic significance of the immunohistochemical expression of O(6)-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas. Neuropathology 29:379–388CrossRefPubMed

20.

Nakasu S, Fukami T, Baba K et al (2004) Immunohistochemical study for O⁶-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol 70:333–340CrossRefPubMed

21.

Sonoda Y, Kumabe T, Watanabe M et al (2009) Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir (Wien) 151:1349–1358CrossRef

22.

Yachi K, Watanabe T, Ohta T et al (2008) Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas. Int J Oncol 33:469–475PubMed

23.

Cloughesy TF, Yoshimoto K, Nghiemphu P et al (2008) Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8CrossRefPubMed

24.

Mellinghoff IK, Wang MY, Vivanco I et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024CrossRefPubMed

25.

Kleihues P, Burger PC, Aldape KD, Brat DJ et al (2007) Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD et al (eds) WHO classification of tumours of the central nervous system, 4th edn. IARC, Lyon, pp 33–49

26.

Eoli M, Pollo B, Bianchessi F et al (2006) Molecular markers of gliomas: a clinical approach. Neurol Res 28:538–541CrossRefPubMed

27.

Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466CrossRefPubMed

28.

Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003CrossRefPubMed

29.

Stupp R, Hegi ME, Mark R et al (2007) Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25:4127–4136CrossRefPubMed

30.

Gerson SL (2002) Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20:2388–2399CrossRefPubMed

31.

Srivenugopal KS, Yuan XH, Friedman HS et al (1996) Ubiquitination-dependent proteolysis of O⁶-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O⁶-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochemistry 35:1328–1334CrossRefPubMed

32.

Zaidi NH, Liu L, Gerson SL (1996) Quantitative immunohistochemical estimates of O⁶-alkylguanine-DNA alkyltransferase expression in normal and malignant human colon. Clin Cancer Res 2:577–584PubMed

Title: Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue
Authors: Yukie Araki
Masahiro Mizoguchi
Koji Yoshimoto
Tadahisa Shono
Toshiyuki Amano
Akira Nakamizo
Satoshi O. Suzuki
Toru Iwaki
Tomio Sasaki
Publication date: 01-02-2011
Publisher: Springer Japan
Published in: Brain Tumor Pathology / Issue 1/2011
Print ISSN: 1433-7398
Electronic ISSN: 1861-387X
DOI: https://doi.org/10.1007/s10014-010-0004-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Angiogenesis and invasion in glioma

Precise comparison of protoporphyrin IX fluorescence spectra with pathological results for brain tumor tissue identification

Epithelioid glioblastoma changed to typical glioblastoma: the methylation status of MGMT promoter and 5-ALA fluorescence

Persistent roles of signal transduction of platelet-derived growth factor B in genesis, growth, and anaplastic transformation of gliomas in an in-vivo serial transplantation model

A case of atypical teratoid/rhabdoid tumor in an adult, with long survival

Glioma-initiating cells and molecular pathology: implications for therapy